

PRODUCT INFORMATION

Common Name	Hu5F9-G4
Synonyms	CD47;MER6;IAP
Conjugate	Unconjugated
Applications	ELISA; Flow Cyt
Recommended Dilutions	ELISA 1:5000-10000; Flow Cyt 1:100
Formulation & Reconstitution	Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution.
Host Species	Homo sapiens
IgG type	Human IgG1 – kappa
Reactivity	Human
Target	CD47
Uniprot ID	Q08722
Description	Anti-CD47 (magrolimab biosimilar; IgG1) mAb
Delivery	In Stock
Storage & Shipping	Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.
Background	Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.
Usage	Research use only



Human CD47, mFc-His tagged protein ELISA

0.1 µg of Human CD47, mFc-His tagged protein per well




Figure 1. ELISA plate pre-coated by 1 µg/ml (100 µl/well) Human CD47, mFc-His tagged protein PME100008 can bind Anti-CD47[magrolimab biosimilar]IgG1 BME100050 in a linear range of 3.2-16.0 ng/ml.




Figure 2. Jurkat cell line were surface stained with anti-CD47 (BME100050) (Blue histogram) and isotype control (Red histogram) 1µg/ml followed by Alexa 488-conjugated Goat anti-Human IgG secondary antibody.






Figure 3. Flow cytometry analysis of antigen binding of anti-human CD47 mAb(BME100050).

(A) BME100050 does not bind to CHO-S cells that do not express CD47.

(B) A clear peak shift of BME100050 was seen compared to the control when incubated with CD47-expressing 8226 cells, indicating strong binding of BME100050 to CD47. Antibodies were incubated at 5 µg/mL.

